85002-74-0

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(CyclopropylMethoxy)-4-nitrobenzene is used as a precursor for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of new compounds with potential therapeutic applications.
Used in Research and Development Laboratories:
CPNB is utilized as a building block in research and development laboratories for the creation of new chemical compounds. Its properties make it a valuable tool in the field of medicinal chemistry and drug discovery.
Used in Medicinal Chemistry and Drug Discovery:
1-(CyclopropylMethoxy)-4-nitrobenzene is used as a structural component in medicinal chemistry and drug discovery. Its unique properties contribute to the development of novel compounds with potential applications in treating various medical conditions.
Safety Precautions:
When handling 1-(CyclopropylMethoxy)-4-nitrobenzene, it is crucial to take safety precautions due to its toxic nature. It may cause irritation to the skin, eyes, and respiratory system, so proper protective equipment and handling procedures should be followed to minimize risks.

Upstream product

• 100-02-7 4-nitro-phenol 
• 7051-34-5 cyclopropylcarbinyl bromide 
• 2516-33-8 Cyclopropylmethanol 
• 100-00-5 4-chlorobenzonitrile 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 74773-28-7 5-(4-Cyclopropylmethoxy-benzyl)-thiazolidine-2,4-dione 
• 85003-34-5 2-Chloro-3-(4-cyclopropylmethoxy-phenyl)-propionic acid methyl ester 
• 122828-48-2 4-(cyclopropylmethoxy)benzenamine 

Relevant academic research and scientific papers

Aryl Ether Syntheses via Aromatic Substitution Proceeding under Mild Conditions

In this study, mild conditions for aromatic substitutions during the syntheses of aryl ethers were developed. In the reaction conditions, the choices of solvent, base, and the sequence for the addition of the reagents proved important. A wide variety of alcohols were used directly as nucleophiles and smoothly reacted with aryl chlorides that possessed either a nitro or a cyano group at either the ortho- or para-position. Controlled experiments we performed suggested that the reaction underwent a charge-transfer process mediated by a combination of DMF and tert-BuOK.

ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF

The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of α7 nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on α7 nAChRs in a mammal by administering an effective amount of a compound of Formula I.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

Fused ring compound and use thereof

The present invention provides a compound represented by the formula: wherein the symbols are as described in the specification, or a salt thereof, which is useful for preventing/treating eicosanoid-associated diseases such as atherosclerosis, diabetes, obesity, atherothrombosis, asthma, fever, pain, cancer, rheumatism, osteoarthritis and atopic dermatitis, and which has an excellent pharmacological action, physicochemical properties, etc.

New β-alanine derivatives are orally available glucagon receptor antagonists

A weak human glucagon receptor antagonist with an IC50 of 7 μM was initially found by screening of libraries originally targeted to mimic the binding of the glucagon-like peptide (GLP-1) hormone to its receptor. Optimization of this hit for binding affinity for the glucagon receptor led to ligands with affinity in the nanomolar range. In addition to receptor binding, optimization efforts were made to stabilize the molecules against fast metabolic turnover. A potent antagonist of the human human glucagon receptor was obtained that had 17% oral availability in rats with a plasma half-life of 90 min. The major metabolites of this lead were identified and used to further optimize this series with respect to pharmacokinetic properties. This final optimization led to a potent glucagon antagonist that was orally available in rats and dogs and was efficacious in lowering blood glucose levels in a diabetic animal model.

GLUCAGON ANTAGONISTS/INVERSE AGONISTS

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-

Determining the σ-donor ability of the cyclopropane C-C bond

The low temperature crystal structures of ester and ether derivatives of varying electron demand, derived from cyclopropylmethanol 8 and dicyclopropylmethanol 9, have been determined. These structures show a very strong response of the C-OR bond distance to the electron demand of the OR substituent, demonstrating the strong σ-donor ability of the strained C-C bonds in the cyclopropane ring. The Royal Society of Chemistry 2005.

Glucagon antagonists/inverse agonists

Disclosed is a novel class of compounds of formula (I) wherein V, A, Y, Z, R1, E, X and D are as defined in the specification. These compounds act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor, the compounds are suitable for treating or preventing glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.